FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889840028> ?p ?o ?g. }

• W2889840028 endingPage "653" @default.
• W2889840028 startingPage "652" @default.
• W2889840028 abstract "To the Editors Acetazolamide is a sulfa-like moiety, a potent nonspecific inhibitor of carbonic anhydrase enzymes.1 It came to medical use in 1952. It is a safe, effective, very economically priced, generic drug, which is in the World Health Organization list of essential drugs. Acetazolamide is available in oral and intravenous form.2 Acetazolamide is indicated for centrencephalic epilepsies, idiopathic intracranial hypertension, secondary glaucoma, and preoperatively in acute angle closure glaucoma where delay of surgery is desired to lower intraocular pressure.2 It appears to have beneficial effect in psychogenic polydipsia.3 Common adverse effects of acetazolamide include tingling,palinopsia, dizziness, diuresis, tiredness, confusion, anorexia, and weight loss. One of the common adverse effects of the antipsychotic drugs is weight gain and metabolic adverse effects.4 Given the treatment compliance associated with weight gain and obesity, clinicians should monitor weight during the course of antipsychotic therapy and consider switching agents if excessive weight gain occurs.5 Body weight and metabolic risk profile in patients receiving atypical antipsychotic medications need to be effectively managed with a weight control program including physical activity, which is difficult in illness such as schizophrenia.6 Topiramate is an anticonvulsant that reportedly confers weight loss in patients receiving doses up to 300 mg/d.7 Topiramate appears to inhibit specific carbonic anhydrase enzymes II and V compared with azetazolamide, which is a nonspecific inhibitor of carbonic anhydrase enzymes and has been demonstrated to decrease lipogenesis in adipose cells in vitro cell culture studies.1 Zonisamide, another antiepileptic drug, also a carbonic anhydrase inhibitor,8 is known to cause weight loss in adolescents9 and adults.10 Patients with idiopathic intracranial hypertension and mild visual loss assigned to either acetazolamide or placebo, all of whom received a 6-month telephone-based weight loss intervention, lost an average of 5.9% of initial body weight, consistent with the NHLBI (National Heart Lung and Blood Institute) guidelines of 5% to 10% of body weight loss for clinically significant health benefit.11 Ophthalmologists have concerns that acetazolamide retards weight gain when given to children. In a retrospective chart review, 22 well children with glaucoma taking oral acetazolamide for 3 months or more showed poor weight gain in a small subset of children.12 Fifteen consecutive female patients with idiopathic intracranial hypertension associated with obesity were studied to determine the weight loss associated with resolution of papilloedema. Patients underwent weight loss on treatment with acetazolamide during the 24-week period. Weight loss of 3.3% ± 0.5% (mild) was observed among patients having a 1-grade change in papilloedema and 6.2% ± 0.6% was associated with a 3-grade (marked) change in papilloedema. Approximately 6% weight loss was associated with resolution of marked papilloedema in these patients.13 A young obese lady gained significant weight after commencing risperidone and later developed headache and blurred vision. She was diagnosed to have benign intracranial hypertension due to risperidone usage. Withdrawing the offending drug and addition of acetazolamide 500 mg twice daily (given for benign intracranial hypertension) led to weight loss and drastically improved her symptoms within a month. Acetazolamide probably helped in recovery by diuresis.14 A 49-year-old obese patient who was started on acetazolamide 250-mg twice daily had significant weight loss of 11.5 lb (5.21 kg) over 4 weeks similar to topiramate.1 In a study, when acetazolamide was given to 30 patients of which puberal periodic psychosis (6 cases), presenile atypical psychosis (7 cases), atypical psychosis (8 cases), atypical manic-depressive psychosis (2 cases), and atypical schizophrenia (7 cases), some extent of therapeutic effects of acetazolamide (500–1000 mg) as an antipsychotic was obtained in approximately 70% of the patients. High therapeutic effects were particularly observed in puberal periodic psychosis, presenile atypical psychosis, and atypical psychosis. Acetazolamide showed effectiveness in 10 of the 13 cases to which lithium carbonate and carbamazepine were ineffective. Acetazolamide was considered to have antipsychotic and prophylactic effects on atypical psychosis. Adverse effects were rarely observed in the study, and acetazolamide had a high safety margin.15 Twenty-four chronic schizophrenia patients were treated successfully with the addition of acetazolamide plus thiamine to their unchanged existing therapies in a double-blind, placebo-controlled cross-over study. Therapeutic effects were measured by the scale for the assessment of positive symptoms and the scale for the assessment of negative symptoms. Overall 50% of the patients showed improvement on all the assessment scales.16 CONCLUSIONS Several clinical studies have reported weight loss as an adverse effect of acetazolamide, and it has shown some beneficial effects in treating psychosis (hence no risk of increasing the primary illness). We conclude, based on the associated weight loss and the apparent improvement in psychotic symptoms, that randomized controlled clinical trials of acetazolamide in antipsychotic-related weight gain are indicated to confirm the associations. Anil Kakunje, DPM, MD Department of Psychiatry Yenepoya Medical College Yenepoya University Mangalore, India [email protected]Ashwini Prabhu, MSc, PhDSindhu Priya ES, M.Pharm Yenepoya Research Centre Yenepoya University Mangalore, IndiaRavichandra Karkal, MDRahyanath K. Pookoth, MSc Department of Psychiatry Yenepoya Medical College Yenepoya University Mangalore, IndiaRekha PD, PhD Yenepoya Research Centre Yenepoya University Mangalore, India" @default.
• W2889840028 created "2018-09-27" @default.
• W2889840028 creator A5034052322 @default.
• W2889840028 creator A5034974722 @default.
• W2889840028 creator A5047227469 @default.
• W2889840028 creator A5052164023 @default.
• W2889840028 creator A5060096095 @default.
• W2889840028 creator A5064118741 @default.
• W2889840028 date "2018-12-01" @default.
• W2889840028 modified "2023-09-25" @default.
• W2889840028 title "Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia" @default.
• W2889840028 cites W1742966305 @default.
• W2889840028 cites W2003012354 @default.
• W2889840028 cites W2018343495 @default.
• W2889840028 cites W2027892169 @default.
• W2889840028 cites W2037740834 @default.
• W2889840028 cites W2045866203 @default.
• W2889840028 cites W2057911972 @default.
• W2889840028 cites W2092611047 @default.
• W2889840028 cites W2115767391 @default.
• W2889840028 cites W2127585882 @default.
• W2889840028 cites W2157539737 @default.
• W2889840028 cites W2167683515 @default.
• W2889840028 cites W2282832414 @default.
• W2889840028 cites W2406197272 @default.
• W2889840028 cites W2141794269 @default.
• W2889840028 doi "https://doi.org/10.1097/jcp.0000000000000940" @default.
• W2889840028 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6221403" @default.
• W2889840028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30192255" @default.
• W2889840028 hasPublicationYear "2018" @default.
• W2889840028 type Work @default.
• W2889840028 sameAs 2889840028 @default.
• W2889840028 citedByCount "4" @default.
• W2889840028 countsByYear W28898400282020 @default.
• W2889840028 countsByYear W28898400282021 @default.
• W2889840028 countsByYear W28898400282023 @default.
• W2889840028 crossrefType "journal-article" @default.
• W2889840028 hasAuthorship W2889840028A5034052322 @default.
• W2889840028 hasAuthorship W2889840028A5034974722 @default.
• W2889840028 hasAuthorship W2889840028A5047227469 @default.
• W2889840028 hasAuthorship W2889840028A5052164023 @default.
• W2889840028 hasAuthorship W2889840028A5060096095 @default.
• W2889840028 hasAuthorship W2889840028A5064118741 @default.
• W2889840028 hasBestOaLocation W28898400281 @default.
• W2889840028 hasConcept C118552586 @default.
• W2889840028 hasConcept C126322002 @default.
• W2889840028 hasConcept C134018914 @default.
• W2889840028 hasConcept C147583825 @default.
• W2889840028 hasConcept C181199279 @default.
• W2889840028 hasConcept C185592680 @default.
• W2889840028 hasConcept C197934379 @default.
• W2889840028 hasConcept C2775914622 @default.
• W2889840028 hasConcept C2776412080 @default.
• W2889840028 hasConcept C2777138316 @default.
• W2889840028 hasConcept C2777405951 @default.
• W2889840028 hasConcept C2777482430 @default.
• W2889840028 hasConcept C2777683783 @default.
• W2889840028 hasConcept C2778076468 @default.
• W2889840028 hasConcept C2778186239 @default.
• W2889840028 hasConcept C2780320433 @default.
• W2889840028 hasConcept C2780494398 @default.
• W2889840028 hasConcept C511355011 @default.
• W2889840028 hasConcept C544821477 @default.
• W2889840028 hasConcept C55493867 @default.
• W2889840028 hasConcept C71924100 @default.
• W2889840028 hasConcept C98274493 @default.
• W2889840028 hasConceptScore W2889840028C118552586 @default.
• W2889840028 hasConceptScore W2889840028C126322002 @default.
• W2889840028 hasConceptScore W2889840028C134018914 @default.
• W2889840028 hasConceptScore W2889840028C147583825 @default.
• W2889840028 hasConceptScore W2889840028C181199279 @default.
• W2889840028 hasConceptScore W2889840028C185592680 @default.
• W2889840028 hasConceptScore W2889840028C197934379 @default.
• W2889840028 hasConceptScore W2889840028C2775914622 @default.
• W2889840028 hasConceptScore W2889840028C2776412080 @default.
• W2889840028 hasConceptScore W2889840028C2777138316 @default.
• W2889840028 hasConceptScore W2889840028C2777405951 @default.
• W2889840028 hasConceptScore W2889840028C2777482430 @default.
• W2889840028 hasConceptScore W2889840028C2777683783 @default.
• W2889840028 hasConceptScore W2889840028C2778076468 @default.
• W2889840028 hasConceptScore W2889840028C2778186239 @default.
• W2889840028 hasConceptScore W2889840028C2780320433 @default.
• W2889840028 hasConceptScore W2889840028C2780494398 @default.
• W2889840028 hasConceptScore W2889840028C511355011 @default.
• W2889840028 hasConceptScore W2889840028C544821477 @default.
• W2889840028 hasConceptScore W2889840028C55493867 @default.
• W2889840028 hasConceptScore W2889840028C71924100 @default.
• W2889840028 hasConceptScore W2889840028C98274493 @default.
• W2889840028 hasIssue "6" @default.
• W2889840028 hasLocation W28898400281 @default.
• W2889840028 hasLocation W28898400282 @default.
• W2889840028 hasLocation W28898400283 @default.
• W2889840028 hasLocation W28898400284 @default.
• W2889840028 hasLocation W28898400285 @default.
• W2889840028 hasOpenAccess W2889840028 @default.
• W2889840028 hasPrimaryLocation W28898400281 @default.
• W2889840028 hasRelatedWork W1480991552 @default.
• W2889840028 hasRelatedWork W148523542 @default.

• next